GLP-1 Receptor Agonists Linked to Reduced Peripheral Artery Disease Events in Cardiovascular Risk Patients
Early signals from cardiovascular outcome trials indicate GLP-1 agonists may improve peripheral artery disease outcomes through anti-inflammatory and vascular mechanisms. This expands potential indications beyond glycemic control and weight loss. Confirmation requires dedicated RCTs measuring limb-specific endpoints.
The STAT report highlights emerging signals from ongoing GLP-1 programs, but overlooks how these align with the SELECT trial's primary results published in NEJM. That 17,604-patient RCT demonstrated 20% relative risk reduction in MACE with semaglutide versus placebo, with limb ischemia and amputation components showing consistent directional benefit in prespecified subgroups. Observational data from large claims databases further suggest lower PAD progression rates among GLP-1 initiators compared to other antidiabetic agents, though confounding by indication remains possible.
Novo Nordisk: STRIDE trial reports 15% or greater reduction in PAD-related hospitalizations at 3 years in 2027 readout
Sources (2)
- [1]SELECT Trial Primary Results(https://www.nejm.org/doi/full/10.1056/NEJMoa2307563)
- [2]Meta-analysis of GLP-1 and Vascular Events(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00001-2/fulltext)